Geisinger Impact on Type 2 Diabetes Patient Outcomes
John W. Kennedy MD
AMGA CMO & President AMGA Foundation
November 2019
Disclosure

• Notice of Requirements for Successful Completion: For successful completion, participants are required to be in attendance in the full activity, complete and submit the program evaluation at the conclusion of the educational event.

• Presenter Conflicts Of Interest and Financial Relationships Disclosures: NONE

• Disclosure of Relevant Financial Relationships and Mechanism to Identify and Resolve Conflicts of Interest: No conflicts of interest

• Non-Endorsement Of Products: Accredited status does not imply endorsement by AADE, ANCC, or ACPE of any commercial products displayed in conjunction with this educational activity.

• Off-Label Use: Participants will be notified by speakers to any product used for a purpose other than that for which it was approved by the Food and Drug Administration.
Objectives

• 1. Describe the national scope of the Together2Goal Campaign and the core measures that comprise the bundle of diabetes outcome measures

• 2. Recognize the relationship between Type 2 Diabetes and Cardiovascular Disease and assess the performance of the Innovator Track participants in improving patient health

• 3. Compare the use of retinal screening cameras embedded in primary care clinics to traditional specialty referral workflows and evaluate the impact on population health for patients with Type 2 Diabetes and diabetic retinopathy
AMGA Trade Association

Indispensable Resource

Population Health

Innovation Across Systems
AMGA: By the Numbers

440+
Medical group and health system members

175,000
Physicians practicing at AMGA member groups

120 million
Americans receiving care from our members

1 in 3
Americans visiting AMGA-affiliated providers
AMGA Foundation

- **Mission**
  AMGA Foundation enables medical groups and other organized systems of care to consistently improve health and health care.

- **Vision**
  The AMGA Foundation serves as a catalyst, connector and collaborator for translating the evidence of what works best in improving health and health care in everyday practice.
Foundation Programs

Acclaim Award

Best Practices Learning Collaboratives

National Campaigns
Campaign Goal:
Improve care for 1 million people with Type 2 diabetes by 2021
Together 2 Goal® Reach

- 150 groups in 36 states
- 61,000 FTE physicians
- 2.0 million patients with Type 2 diabetes
Together 2 Goal® Non-Profit Partners & Supporting Organizations
Together 2 Goal® Extension Corporate Collaborators

Presenting Corporate Collaborator

Founding Corporate Collaborator

Innovator Track Corporate Collaborator

Distinguished Data and Analytics Corporate Collaborator

Contributing Corporate Collaborator
# Data Reporting Tracks

<table>
<thead>
<tr>
<th></th>
<th>Basic</th>
<th>Core: Bundle</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C control &lt; 8 percent</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>BP control &lt; 140/90 mmHg</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Lipid management</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Medical attention for nephropathy</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Bundle Measure</td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>
Continuous Quality Improvement: Lesson #1

• Improving outcomes for patients
• Improving more than other high performing health systems in benchmark
• Medical Attention to Nephropathy

https://www.facebook.com/StarsAlignCHI/
Nephropathy – 2016 Q1 (Baseline)

790,000 patients with type 2 diabetes, across 65 AMGA member organizations
Nephropathy – 2019 Q1 (Year 3)

930,000 patients with type 2 diabetes, across 65 AMGA member organizations
Continuous Quality Improvement: Lesson#2

• Improving Patient Outcomes
• Improvement is outpaced by other high performing health systems
• Lipid Management

790,000 patients with type 2 diabetes, across 65 AMGA member organizations

T2G® 2016 Q1: Proportion of Patients with Lipid Management

68.7%
Lipid Management – 2019 Q1 (Year 3)

930,000 patients with type 2 diabetes, across 65 AMGA member organizations

T2G® 2019 Q1: Proportion of Patients with Lipid Management

73.3%
Continuous Quality Improvement: Lesson#3

• Shifting Sands result in reduction in quality metric performance
• Peer group of high performing health systems improve
• HgbA1c%

https://jia.sipa.columbia.edu/shifting-sands-global-order
HbA1c < 8.0 – 2016 Q1 (Baseline)

850,000 patients with type 2 diabetes, across 70 AMGA member organizations

T2G® 2016 Q1: Proportion of Patients with HbA1c in Control (< 8%)
HbA1c < 8.0 – 2019 Q1 (Year 3)

1,010,000 patients with type 2 diabetes, across 70 AMGA member organizations
T2DM T2G cohort over time

- For most groups the T2G cohort (measure denominator) is fairly steady with slight growth over time.

The population growth for these groups is primarily due to acquisitions.

Geisinger denominator growth primarily due to new diagnosis.
Understanding Overall Improvement

• Diabetes Bundle
• % patients with 4 out of 4 measures in control
  – A1c
  – BP
  – HTN
  – Nephropathy

T2G Bundle – 2016 Q1 (Baseline)

790,000 patients with type 2 diabetes, across 65 AMGA member organizations

T2G® 2016 Q1: Proportion of Patients Compliant with All Elements of the T2G Bundle
T2G Bundle – 2019 Q1 (Year 3)

930,000 patients with type 2 diabetes, across 65 AMGA member organizations

T2G® 2019 Q1: Proportion of Patients Compliant with All Elements of the T2G Bundle
## Geisinger T2G

<table>
<thead>
<tr>
<th>Metric</th>
<th>2016 Q1</th>
<th>2017 Q1</th>
<th>2018 Q1</th>
<th>2019 Q1</th>
<th>Δ 2016 – 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>T2DM prevalence</td>
<td>16.9%</td>
<td>16.8%</td>
<td>16.7%</td>
<td>18.0%</td>
<td>+ 1.1%</td>
</tr>
<tr>
<td>HbA1c &lt; 8.0</td>
<td>63.7%</td>
<td>61.9%</td>
<td>63.3%</td>
<td>62.5%</td>
<td>– 1.2%</td>
</tr>
<tr>
<td>BP &lt; 140/90</td>
<td>76.8%</td>
<td>76.8%</td>
<td>76.5%</td>
<td>76.8%</td>
<td>+ 0.0%</td>
</tr>
<tr>
<td>Nephropathy</td>
<td>80.9%</td>
<td>93.6%</td>
<td>94.2%</td>
<td>94.0%</td>
<td>+ 13.1%</td>
</tr>
<tr>
<td>Lipid management</td>
<td>80.8%</td>
<td>81.4%</td>
<td>82.1%</td>
<td>83.7%</td>
<td>+ 2.9%</td>
</tr>
<tr>
<td>T2G Bundle</td>
<td>34.9%</td>
<td>39.6%</td>
<td>40.6%</td>
<td>40.6%</td>
<td>+ 5.7%</td>
</tr>
</tbody>
</table>
# Geisinger T2G

<table>
<thead>
<tr>
<th>Metric</th>
<th>2016 Q1</th>
<th>2017 Q1</th>
<th>2018 Q1</th>
<th>2019 Q1</th>
<th>Δ 2016 – 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>T2DM prevalence</td>
<td>16.9%</td>
<td>16.8%</td>
<td>16.7%</td>
<td>18.0%</td>
<td>+ 1.1%</td>
</tr>
<tr>
<td>HbA1c &lt; 8.0</td>
<td>63.7%</td>
<td>61.9%</td>
<td>63.3%</td>
<td>62.5%</td>
<td>- 1.2%</td>
</tr>
<tr>
<td>BP &lt; 140/90</td>
<td>76.8%</td>
<td>76.8%</td>
<td>76.5%</td>
<td>76.8%</td>
<td>+ 0.0%</td>
</tr>
<tr>
<td>Nephropathy</td>
<td>80.9%</td>
<td>93.6%</td>
<td>94.2%</td>
<td>94.0%</td>
<td>+ 13.1%</td>
</tr>
<tr>
<td>Lipid management</td>
<td>80.8%</td>
<td>81.4%</td>
<td>82.1%</td>
<td>83.7%</td>
<td>+ 2.9%</td>
</tr>
<tr>
<td>T2G Bundle</td>
<td>34.9%</td>
<td>39.6%</td>
<td>40.6%</td>
<td>40.6%</td>
<td>+ 5.7%</td>
</tr>
</tbody>
</table>
Tactics to improve HgbA1c & Bundle Control

• Point of Care HgbA1c% testing
• Diabetes Education
• MTM Pharmacist Diabetes Medication Carepath
• Case Management
• Best Practice Alert acknowledgement
• Pre-visit planning--Diabetes Huddles
• Endocrinology Consultation
Improved care for more than
750,000 people
with Type 2 diabetes
New Project: Innovator Track

<table>
<thead>
<tr>
<th>Cardiovascular Disease Cohort</th>
<th>Eye Care Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="stethoscope.png" alt="Stethoscope" /></td>
<td><img src="eye_chart.png" alt="Eye Chart" /></td>
</tr>
</tbody>
</table>
New Project: T2G Diabetes Bundle Best Practices Learning Collaborative
Geographic Distribution of Cohort
**T2G 2018 Q2 (BL): Prevalence of type 2 diabetes among active patient population (Innovator Track Eye Cohort)**

<table>
<thead>
<tr>
<th>Ballad Health</th>
<th>Kelsey Seybold</th>
<th>Baton Rouge</th>
<th>Watson Clinic</th>
<th>Geisinger</th>
<th>Henry Ford</th>
<th>Coastal Carolina</th>
<th>Valley</th>
<th>Utica Park</th>
<th>Prevea</th>
</tr>
</thead>
</table>

©2018 All rights reserved
T2G T2DM patients with documented screening for diabetic retinal disease

12% increase in T2DM patients
(≈ 4,500 newly diagnosed)

4.7% relative improvement
+ 1,262 patients
T2G T2DM patients with documented screening for diabetic retinal disease

22.6% relative improvement
+ 775 patients

21.3% relative improvement
+ 3,148 patients

15.3% relative improvement
+ 462 patients
T2G T2DM patients with documented screening for diabetic retinal disease

- Denominator: Grew from 151,200 to 159,500 T2DM patients
  - 5.4% absolute improvement
  - 11.6% relative improvement
  - 8 of 10 groups saw improvement
    - 3 with relative improvement ~ 5%
    - 5 with relative improvements of 15% – 45%
    - 4 groups with > 1,000 additional patients
- 8,600 additional patients with a documented screening!
New Project: Innovator Track

<table>
<thead>
<tr>
<th>Cardiovascular Disease Cohort</th>
<th>Eye Care Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1" alt="Stethoscope Image" /></td>
<td><img src="image2" alt="Eye Chart Image" /></td>
</tr>
</tbody>
</table>
Participant Interventions

- Provider Education: 10%
- EHR Enhancements: 19%
- Care Redesign/Workflow Improvements: 21%
- Patient Outreach and Education: 16%
- Data/Documentation Improvements: 13%
- Elevate Emphasis within Leadership: 21%

©2018 All rights reserved
Intervention Hot List – Top 5

• #5: Leveraging EHR to better identify or treat risk

Best Practice Alerts

Smart Phrases

Diabetes
Order Sets
Intervention Hot List – Top 5

• #4: Integrating pharmacy team into DM/CVD efforts
Intervention Hot List – Top 5

• #3: Leverage data reports to identify patient gaps

  Registry of DM Patients at Risk for CVD

  List of High-Intensity Statin Candidates

  Unblinded Provider Data re: Prescribing Statins, Evidence-Based CVOT Meds
Intervention Hot List – Top 5

• #2: Educate providers on relevant topics

- Link between Diabetes and CVD
- CVD Risk Reduction Guidelines
- Statins
- Aspirin
Intervention Hot List – Top 5

• #1: EHR integration of ASCVD risk calculator
Campaign Extension into 2021

T2G EXTENDS TO 2021

2-year extension

- March 2016 Launch
- 2017
- 2018 750K Milestone
- April 1, 2019 Extension Begins
- 2020
- March 31, 2021 Completion
New Research

Publications & Presentations from AMGA Analytics

Bridging the Gaps
From diabetes screening to diagnosis to treatment

Many millions of people in the United States are undiagnosed and untreated for diabetes, and 1 in 3 adults have prediabetes. Over 28% of adults have prediabetes and 8.5% have diabetes. This issue is of critical importance as it is the second leading cause of death in the U.S. (after heart disease), and people with diabetes have increased risks of death due to the severe health complications caused by the disease. To address diabetes in the United States, three areas of increase in screening rates are being targeted:

- Increased screening in at-risk populations
- Increased screening in underserved populations
- Increased screening in individuals with prediabetes

In June 2019, the National Diabetes Prevention Program (NDPP) of the Centers for Disease Control, only 21% were screened in the U.S. In addition, we focused on the self-management as a result of screening.

The objective was to measure the time from a positive diabetes screening test to appropriate follow-up action—i.e., diagnosis, pharmacotherapy treatment, and/or lifestyle change.

Figure 1 Three-Month Follow-up after a Positive Diabetes Screen, Overall and by Healthcare Organization (HCO)

Learning Health Systems, Creative Analytics, and Population Health Management

Rebecca Caramia, PhD, MPH, MA
Director, Research & Analytics, AMGA
Unique Real-World Evidence (RWE) Population Health Management
April 5, 2018 | Dallas, TX

Characterizing Clinical Inertia Among Patients with Type 2 Diabetes

Nabil El Hamelsky, MD
Chief Medical Officer, AMGA
April 5, 2018 | Dallas, TX

©2018 All rights reserved
New Offering: Revamped Website

Welcome to the Together 2 Goal® campaign website! We are proud to collaborate with medical groups, health systems, partners, and corporate collaborators across the nation with the goal of improving care for 1 million people with Type 2 diabetes. We hope our website will provide you with the tools and resources needed to more effectively manage your patients with Type 2 diabetes. AMGA members interested in enrolling can learn more here.
New Offering: Toolkit Supplement
New Offering: Plank Mentors
Campaign Planks

**EMPOWER PATIENTS**
- Build an Accountable Diabetes Team
- Integrate Emotional & Behavioral Support
- Refer to Diabetes Self-Management Education & Support Programs

**IMPROVE CARE DELIVERY**
- Conduct Practice-Based Screening
- Adopt Treatment Algorithm
- Measure HbA1c Every 3-6 months
- Assess & Address Risk of Cardiovascular Disease
- Contact Patients Not at Goal & with Therapy Change within 30 Days

**LEVERAGE INFORMATION TECHNOLOGY**
- Use a Patient Registry
- Embed Point-of-Care Tools
- Publish Transparent Internal Reports

©2018 All rights reserved
Together 2 Goal® Welcomes Plank Mentors!